New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 30, 2013
12:41 EDTMYGNMyriad Genetics price target lowered to $20 from $32 at Goldman
Goldman lowered its estimates and price target for Myriad Genetics after the CMS confirmed a 49% cut to reimbursements for BRCA 1&2 gene tests. The firm keeps a Neutral rating on the stock.
News For MYGN From The Last 14 Days
Check below for free stories on MYGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for MYGN

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use